A Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Mild COVID-19
Latest Information Update: 14 Mar 2024
At a glance
- Drugs Bempegaldesleukin (Primary)
- Indications COVID-19 respiratory infection
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Nektar Therapeutics
- 27 Sep 2021 Status changed from active, no longer recruiting to completed.
- 20 May 2021 Status changed from recruiting to active, no longer recruiting.
- 28 Apr 2021 Planned End Date changed from 27 Mar 2021 to 5 Sep 2021.